

Table S1A

**Characteristics of primary breast cancer in 37 patients
with metastatic breast cancer**

Characteristic	No. (%)
<u>Type of surgery</u>	
Breast conserving	11 (29.7)
Mastectomy	21 (56.8)
No surgery	4 (10.8)
Other	1 (2.7)
<u>Histology</u>	
Ductal carcinoma	26 (70.3)
Lobular carcinoma	3 (8.11)
Carcinoma, unspecified	5 (13.5)
Unknown	3 (8.11)
<u>Size</u>	
≤10 mm	2 (5.41)
11-20 mm	11 (29.7)
21-50 mm	11 (29.7)
≥50 mm	6 (16.2)
Unknown or no surgery	7 (18.9)
<u>Lymph node involvement</u>	
0 or micrometastases	9 (24.3)
1-3	10 (27.0)
4-9	7 (18.9)
≥10	3 (8.11)
Unknown or no surgery	8 (21.6)
<u>Grade</u>	
I	5 (13.5)
II	11 (29.7)
III	9 (24.3)
Unknown	12 (32.4)
<u>ER-status</u>	
Positive	29 (78.4)
Negative	4 (10.8)
Unknown	4 (10.8)
<u>HER2-status</u>	
Positive	9 (24.3)
Normal	18 (48.6)
Unknown	10 (27.0)
<u>Medical treatment</u>	
Neo-adjuvant and adjuvant	9 (24.3)
Adjuvant only	22 (59.5)
No medical treatment	6 (16.2)
	37 (100)

ER: Estrogen receptor, HER2: Human Epidermal Growth Receptor 2. Provided with permission and courtesy of Vogens et al. (PERCIST for longitudinal response monitoring in metastatic breast cancer; under review).

Table S1B

**Biomarker profile of metastatic lesion and location of biopsy in
37 patients with metastatic breast cancer**

Characteristic	No. (%)
<u>ER-status</u>	
Positive	30 (81.1)
Negative	6 (16.2)
Unknown	1 (2.7)
<u>HER2-status</u>	
Positive	9 (24.3)
Normal	23 (62.2)
Unknown	5 (13.5)
<u>Location of biopsy*</u>	
Bone	11 (29.7)
Liver	6 (16.2)
Brain	1 (2.7)
Lung	2 (5.4)
Lymph node	9 (24.3)
Breast	2 (5.4)
Skin	2 (5.4)
Other	4 (10.8)
	37 (100)

*Location of biopsy from a metastatic lesion, ER: Estrogen receptor, HER2: Human Epidermal Growth Receptor 2. Provided with permission and courtesy of Vogsen et al. (PERCIST for longitudinal response monitoring in metastatic breast cancer; under review).